

| Code | Name | Partner | Disease domain | Mode of action | Current Phase / (Expected) Start date | (Expected) Completion date | Remarks |
|----------|------|-------------------------|--|---|--|------------------------------|--|
| GLPG0187 | | | Stomach cancer | Inhibitor | Phase 1 | | Stopped after Phase 1 |
| GLPG0189 | | Janssen | RA (Rheumatoid Arthritis) | MAMPK/AMPK inhibitor | Phase 1 | | Stopped after Phase 2 |
| GLPG030x | | | Undisclosed indication | | | | Stopped Preclinical |
| GLPG0492 | | | MD (Muscular Dystrophy) | Androgen receptor modulator | Phase 1 | | Stopped after Phase 1 |
| GLPG0505 | | Before Glaxo SmithKline | DA (Dyspareunia) | JAK1 inhibitor | Phase 1 | | Backup of GLPG0778 |
| GLPG0538 | | igotrom/ Jyselca | RA (Rheumatoid Arthritis) | JAK1 inhibitor | Phase 3 (EINCH 4) | Expected May '20 | Approved in Europe, Japan |
| | | | UC (Ulcerative Colitis) | JAK1 inhibitor | Phase 3 (SELECTION 1) | Completed May '20 | JAP filing SH21, EU App Jh21 |
| | | | CD (Crohn's Disease) | JAK1 inhibitor | Phase 3 (DIVERSITY 1) | Expected Nov '21 | |
| | | | Small bowel CD (Crohn's Disease) | JAK1 inhibitor | Phase 2 | Completed July '20 | |
| | | | Perianal Fistulizing CD (Crohn's Disease) | JAK1 inhibitor | Phase 2 (DIVERGENCE 2) | Completed Jan '21 | |
| | | | SS (Sjogren Syndrome) | JAK1 inhibitor | Phase 2 | Completed | |
| | | | AS (Ankylosing Spondylitis) (Bechterew) | JAK1 inhibitor | Phase 3 (SEALION 1, 2) | Expected July '24 | |
| | | | RA (Rheumatoid Arthritis) | JAK1 inhibitor | Phase 3 (SPINDIAN 3,2) | Expected Oct '21 and May '22 | |
| | | | CEL (Cutaneous Lupus Erythematosus) | JAK1 inhibitor | Phase 2 | Completed Dec '19 | |
| | | | LMN (Lupus Nephritis) | JAK1 inhibitor | Phase 2 | Completed Feb '20 | |
| | | | Dermis | JAK1 inhibitor | Phase 2 (HUMBOLDT) | Expected July '22 | |
| GLPG0778 | | Glaxo SmithKline | Lupus, Psoriasis, UC | JAK1 inhibitor | | | Stopped after Phase 2a |
| GLPG080x | | | Undisclosed indication | | | | Stopped Preclinical |
| GLPG0974 | | Before Glaxo SmithKline | IBD (Inflammatory Bowel Disease) | GRK43 inhibitor / FFAR2 | | | Stopped after Phase 2 |
| GLPG098x | | | Undisclosed indication | | | | Stopped Preclinical |
| GLPG1179 | | Before Glaxo SmithKline | Undisclosed indication | | | | Stopped Preclinical |
| GLPG1205 | | Before Janssen | IPF (Idiopathic Pulmonary Fibrosis) | GRK43 inhibitor / FFAR2 | Phase 2b / Expected start in 2021 | | Phase 2 (PNTA) Aug '20 completed |
| GLPG1332 | | Before Servier | DA (Dyspareunia) | | | | Stopped Preclinical |
| GLPG1492 | | | MDA | | | | Stopped Preclinical |
| GLPG1577 | | Before Glaxo SmithKline | Undisclosed indication | | | | Stopped Preclinical |
| GLPG1690 | | Zincwaxstat | IPF (Idiopathic Pulmonary Fibrosis) | Autotaxin inhibitor | Phase 3 (ISABELA) | | Stopped due to unfavorable balance between safety and efficacy |
| | | Before Janssen | SC (Systemic Sclerosis, Scleroderma) | Autotaxin inhibitor | Phase 2 (MOVESA) | | Stopped due to unfavorable balance between safety and efficacy |
| GLPG1790 | | | Triple Negative Breast Cancer | Epine Receptor Tyrosine Kinase inhibitor | | | Stopped Preclinical |
| GLPG1837 | | AbbVie | CF (Cystic Fibrosis) | 1c potentiator | | | Continue with GLPG2451 |
| GLPG1972 | | Servier | DA (Dyspareunia) | ADAMTS-5 inhibitor | Phase 2 (ROCELLA) Aug '18 | Completed Dec '20 | Stopped due to lack of efficacy |
| GLPG209x | | | Undisclosed indication | | | | Stopped Preclinical |
| GLPG2186 | | Before Janssen | CF (Cystic Fibrosis) | GRK43 antagonist/CFTR Potentiator | | | Backup of GLPG1205, Stopped Preclinical |
| GLPG2222 | | AbbVie | CF (Cystic Fibrosis) | 1c C1 corrector | | | Sold to AbbVie |
| GLPG2384 | | Before Janssen | Undisclosed indication | GRK43 antagonist | Preclinical | | Backup of GLPG1205, Still active? |
| GLPG2451 | | AbbVie | CF (Cystic Fibrosis) | 2c potentiator | | | Sold to AbbVie |
| GLPG2534 | | AbbVie | AD (Atopic Dermatitis) | 2b potentiator | Preclinical | | Still active? |
| GLPG2665 | | AbbVie | CF (Cystic Fibrosis) | 1c C2 corrector | | | Stopped, Continue with GLPG2737 |
| GLPG2737 | | Before AbbVie | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 2c C2 corrector | Phase 2, Nov '20 (Recruiting) | Expected Nov '22 | Rights outside CF for GLPG, PKCQ same as ADPKD? |
| GLPG2851 | | AbbVie | CF (Cystic Fibrosis) | 2b C1 corrector | | | Sold to AbbVie |
| GLPG2938 | | AbbVie | IPF (Idiopathic Pulmonary Fibrosis) | GRK43 antagonist/CFTR Potentiator | | | Stopped Preclinical, Continue with GLPG3499 |
| GLPG3067 | | AbbVie | CF (Cystic Fibrosis) | 3c potentiator | | | Sold to AbbVie |
| GLPG3121 | | Glaxo | Inflammation | JAK2/TYK2 inhibitor | Phase 1, Mar '19 | Completed Jun '19 | Stopped after Phase 1 due to lack of PK effect, Active again? |
| GLPG3221 | | AbbVie | CF (Cystic Fibrosis) | 2c C2 corrector | | | Stopped, Continue with GLPG3448 |
| GLPG3332 | | Toledo | IBD (Inflammatory Bowel Disease) | SIK2/3 inhibitor | Phase 1, Jan '19 | Completed Mar '20 | Gen 1 Toledo, Phase 2 PoC expected in 2020 |
| GLPG3499 | | | IPF (Idiopathic Pulmonary Fibrosis) | | Stopped in IPF preclinical | | Still active? |
| GLPG3535 | | Before Calichan | Fibrosis | | Preclinical | | |
| GLPG3672 | | Glaxo | Phase 2/3 | | Phase 3, Oct '20 (Recruiting) | Expected May '21 | Planned Phase 2 in PsA and UC in H2 '21 |
| GLPG3748 | | AbbVie | CF (Cystic Fibrosis) | 4c C2 corrector | | | Sold to AbbVie |
| GLPG3808 | | | Undisclosed indication | | Preclinical | | |
| GLPG3970 | | Toledo | Pain | SIK2/3 inhibitor | Phase 1 (CALISSONIA) | | Gen 2 Toledo (More selective) |
| | | | UC (Ulcerative Colitis) | SIK2/3 inhibitor | Phase 2 (SEA TURTLE), Oct '20 (Recruiting) | Expected Jun '21 | Gen 2 Toledo (More selective) |
| | | | RA (Rheumatoid Arthritis) | SIK2/3 inhibitor | Phase 2 (LADYBUG), Oct '21 (Act, not rec) | Expected April '21 | Gen 2 Toledo (More selective) |
| | | | SS (Sjogren Syndrome) | SIK2/3 inhibitor | Phase 2 (GLIDER), Jan '21 (Recruiting) | Expected May '22 | Gen 2 Toledo (More selective) |
| | | | CEL (Cutaneous Lupus Erythematosus) | SIK2/3 inhibitor | Phase 1 (EAPHONIA), Dec '20 | Expected Mar '22 | Gen 2 Toledo (More selective) |
| GLPG4059 | | | Diabetes Type 2 | Novel MDA that does not hit tripartite, a | Phase 1, Sept '20 (Recruiting) | Expected Apr '21 | |
| GLPG4124 | | Glaxo | Fibrosis | | Preclinical | | |
| GLPG4259 | | Glaxo | Inflammation | | Preclinical | | Backup off? |
| GLPG4389 | | Toledo | RA (Rheumatoid Arthritis) | SIK1 inhibitor | Phase 1, Nov '20 (Recruiting) | Expected July '21 | Gen 3 Toledo (More selective) |
| GLPG4471 | | Glaxo | Inflammation | | | | Backup off? Disease? |
| GLPG4586 | | FIB556 | Fibrosis | | Preclinical | | Gen 2 Toledo (More selective) |
| GLPG4600 | | Toledo | Fibrosis | SIK2/3 inhibitor | | | |
| GLPG4716 | | Dinocemid (DADT-01) | IPF (Idiopathic Pulmonary Fibrosis) | Thiazole inhibitor | Preclinical Phase 2b (~200 patients) | | |
| GLPG4876 | | Toledo | Fibrosis | SIK2/3 inhibitor | | | |
| MDR105 | | Monophos and Novartis | Atopic Dermatitis | IL-37C | | | Stopped after Phase 2 (IGUANA) (GECKO) |

| Legend | |
|-----------------|-------------------------------|
| XXX | Stopped |
| XXX | Active |
| Disease domains | |
| XXX | Fibrosis |
| XXX | Inflammation |
| XXX | Osteoarthritis |
| XXX | Cancer |
| XXX | Other, Undisclosed or Unknown |

Galápagos

Pioneering for patients

We discover We dare We care